aspirin has been researched along with Dementia in 42 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin does not have a large proportional effect on the risk of dementia." | 9.51 | Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022) |
| "Long-term use of low-dose aspirin may reduce the risk for dementia in women with T2D." | 9.34 | Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2020) |
| "To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals." | 9.34 | Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020) |
| "Aspirin and B-vitamins were effective in reducing biochemical factors associated with cognitive impairment in people at risk of dementia." | 9.10 | Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. ( Clarke, R; Harrison, G; Richards, S, 2003) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "Aspirin may be associated with a lower risk of incident dementia in patients with LOD." | 7.96 | Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study. ( Chiu, CC; Huang, CT; Huang, LJ; Liu, CY; Teng, HW; Yang, YH, 2020) |
| "Aspirin does not have a large proportional effect on the risk of dementia." | 5.51 | Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022) |
| " The authors--in view of the increased neuroinflammatory reaction frequently observed during normal brain ageing--suggest the long-term use of "fatty aspirin", an association of DHA and/or NPD1 and aspirin (or nitroaspirin), to postpone, or prevent, the structural neurodegeneration of the brain." | 5.35 | Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type? ( Bria, P; Di Gioia, A; Pomponi, M; Pomponi, MF, 2008) |
| "Long-term use of low-dose aspirin may reduce the risk for dementia in women with T2D." | 5.34 | Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. ( Doi, N; Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Waki, M, 2020) |
| "To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals." | 5.34 | Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020) |
| "Aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo." | 5.27 | Effect of Aspirin on Disability-free Survival in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Donnan, GA; Ernst, ME; Fitzgerald, SM; Gibbs, P; Grimm, R; Johnston, CI; Kirpach, B; Lockery, JE; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Woods, RL, 2018) |
| "Aspirin and B-vitamins were effective in reducing biochemical factors associated with cognitive impairment in people at risk of dementia." | 5.10 | Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. ( Clarke, R; Harrison, G; Richards, S, 2003) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "This review found no evidence that low-dose aspirin buffers against cognitive decline or dementia or improves cognitive test scores in RCTs." | 4.95 | Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis. ( Carvalho, AF; Lin, PY; Maggi, S; Muller, C; Schofield, P; Solmi, M; Stubbs, B; Thompson, T; Tseng, PT; Veronese, N, 2017) |
| "Aspirin may be associated with a lower risk of incident dementia in patients with LOD." | 3.96 | Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study. ( Chiu, CC; Huang, CT; Huang, LJ; Liu, CY; Teng, HW; Yang, YH, 2020) |
| "In this well-monitored geriatric population with chronic AF, including patients with falls and/or dementia, a high percentage were prescribed warfarin (85%), with low rates of stroke, hemorrhage, and death at 12 months despite a low TTR." | 3.75 | Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. ( Billett, HH; Dinglas, C; Freeman, K; Jacobs, LG; Jumaquio, L, 2009) |
| "Our results suggest that dementia is a significant independent determinant of nontreatment with aspirin or warfarin when otherwise indicated for the prevention of recurrent stroke." | 3.70 | Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. ( Desmond, DW; Mohr, JP; Moroney, JT; Paik, MC; Tseng, CL, 1999) |
| "Frailty was associated with the primary composite outcome capturing independent life lived free of major disability and dementia, and increased the rate of persistent physical disability (hazard ratio: 21." | 3.11 | Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing Events in the Elderly Study and Its Predictive Capacity for Disability-Free Survival. ( Beilin, LJ; Ekram, ARMS; Ernst, ME; Espinoza, S; Fitzgerald, S; McNeil, JJ; Murray, AM; Newman, AB; Orchard, SG; Ryan, J; Shah, RC; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2022) |
| "Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels." | 2.82 | Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. ( Chiang, LLW; Hafdi, M; Kwan, J; Myint, PK; Quinn, TJ; Wong, LS, 2022) |
| "Aspirin has higher side effect risks and requires a longer time to achieve benefit." | 2.52 | Primary prevention: do the very elderly require a different approach? ( Schwartz, JB, 2015) |
| "AMI patients with dementia have a higher mortality rate." | 1.91 | Impact of dementia and drug compliance on patients with acute myocardial infarction. ( Chae, IH; Jheon, KH; Kang, SH; Kim, SH; Lee, SY; Lee, W; Myung, W; Suh, JW; Yoon, CH; Youn, TJ, 2023) |
| " The authors--in view of the increased neuroinflammatory reaction frequently observed during normal brain ageing--suggest the long-term use of "fatty aspirin", an association of DHA and/or NPD1 and aspirin (or nitroaspirin), to postpone, or prevent, the structural neurodegeneration of the brain." | 1.35 | Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type? ( Bria, P; Di Gioia, A; Pomponi, M; Pomponi, MF, 2008) |
| "Vascular dementia is a common and potentially reversible type of dementing illness." | 1.27 | Validation of cognitive and functional assessment instruments in vascular dementia. ( Greenough, PG; Hershey, LA; Jaffe, DF; Yang, SL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.90) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 11 (26.19) | 24.3611 |
| 2020's | 16 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, X | 1 |
| Banaszak-Holl, J | 1 |
| Xie, J | 1 |
| Ward, SA | 3 |
| Brodaty, H | 1 |
| Storey, E | 4 |
| Shah, RC | 5 |
| Murray, A | 1 |
| Ryan, J | 4 |
| Orchard, SG | 5 |
| Fitzgerald, SM | 3 |
| McNeil, JJ | 6 |
| Mone, P | 1 |
| Trimarco, B | 1 |
| Santulli, G | 1 |
| Abbasi, J | 1 |
| Parish, S | 1 |
| Mafham, M | 1 |
| Offer, A | 1 |
| Barton, J | 1 |
| Wallendszus, K | 1 |
| Stevens, W | 1 |
| Buck, G | 1 |
| Haynes, R | 1 |
| Collins, R | 1 |
| Bowman, L | 1 |
| Armitage, J | 1 |
| Kristensen, SD | 1 |
| Olesen, KKW | 1 |
| Maeng, M | 1 |
| Hu, Y | 1 |
| Carr, PR | 1 |
| Liew, D | 1 |
| Broder, J | 1 |
| Callander, EJ | 1 |
| Kwan, J | 1 |
| Hafdi, M | 1 |
| Chiang, LLW | 1 |
| Myint, PK | 1 |
| Wong, LS | 1 |
| Quinn, TJ | 2 |
| Rojas-Rozo, L | 1 |
| Vedel, I | 1 |
| Sivananthan, S | 1 |
| Ismail, Z | 1 |
| Khanassov, V | 1 |
| Linda, L | 1 |
| Lee, W | 1 |
| Kang, SH | 1 |
| Kim, SH | 1 |
| Lee, SY | 1 |
| Myung, W | 1 |
| Jheon, KH | 1 |
| Yoon, CH | 1 |
| Suh, JW | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Matsumoto, C | 1 |
| Ogawa, H | 1 |
| Saito, Y | 1 |
| Okada, S | 1 |
| Soejima, H | 1 |
| Sakuma, M | 1 |
| Masuda, I | 1 |
| Nakayama, M | 1 |
| Doi, N | 1 |
| Jinnouchi, H | 1 |
| Waki, M | 1 |
| Morimoto, T | 1 |
| Springer, SP | 1 |
| Mor, MK | 1 |
| Sileanu, F | 1 |
| Zhao, X | 1 |
| Aspinall, SL | 1 |
| Ersek, M | 1 |
| Niznik, JD | 1 |
| Hanlon, JT | 1 |
| Hunnicutt, J | 1 |
| Gellad, WF | 1 |
| Schleiden, LJ | 1 |
| Thorpe, JM | 1 |
| Thorpe, CT | 1 |
| Yang, YH | 1 |
| Chiu, CC | 1 |
| Teng, HW | 1 |
| Huang, CT | 1 |
| Liu, CY | 1 |
| Huang, LJ | 1 |
| Murray, AM | 4 |
| Woods, RL | 4 |
| Wolfe, R | 3 |
| Reid, CM | 3 |
| Nelson, MR | 3 |
| Chong, TTJ | 1 |
| Williamson, JD | 4 |
| Lockery, JE | 3 |
| Trevaks, R | 1 |
| Kirpach, B | 3 |
| Newman, AB | 4 |
| Ernst, ME | 4 |
| Jordan, F | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 1 |
| Devane, D | 1 |
| Lai, SW | 1 |
| Kuo, YH | 1 |
| Liao, KF | 1 |
| Espinoza, S | 1 |
| Ekram, ARMS | 1 |
| Fitzgerald, S | 1 |
| Beilin, LJ | 3 |
| Wolfe, RS | 1 |
| Tonkin, AM | 2 |
| Margolis, KL | 2 |
| Abhayaratna, WP | 2 |
| Stocks, N | 2 |
| Trevaks, RE | 2 |
| Donnan, GA | 2 |
| Gibbs, P | 2 |
| Johnston, CI | 2 |
| Grimm, RH | 1 |
| Veronese, N | 1 |
| Stubbs, B | 1 |
| Maggi, S | 1 |
| Thompson, T | 1 |
| Schofield, P | 1 |
| Muller, C | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Carvalho, AF | 1 |
| Solmi, M | 1 |
| Radziszewska, B | 1 |
| Grimm, R | 1 |
| de Havenon, A | 1 |
| Meyer, C | 1 |
| McNally, JS | 1 |
| Alexander, M | 1 |
| Chung, L | 1 |
| Schwartz, JB | 1 |
| Wang, LP | 1 |
| Zhang, XY | 1 |
| Liu, N | 1 |
| Ma, ZZ | 1 |
| Fang, DS | 1 |
| Golden, LE | 1 |
| Sassoon, P | 1 |
| Cáceda, R | 1 |
| Pomponi, M | 1 |
| Di Gioia, A | 1 |
| Bria, P | 1 |
| Pomponi, MF | 1 |
| Penot, JP | 1 |
| Pradeau, F | 1 |
| Jacobs, LG | 1 |
| Billett, HH | 1 |
| Freeman, K | 1 |
| Dinglas, C | 1 |
| Jumaquio, L | 1 |
| Pirker, S | 1 |
| Baumgartner, C | 1 |
| Dubessy, AL | 1 |
| Ursu, R | 1 |
| Maillet, D | 1 |
| Augier, A | 1 |
| Le Guilloux, J | 1 |
| Carpentier, AF | 1 |
| Belin, C | 1 |
| Clarke, R | 1 |
| Harrison, G | 1 |
| Richards, S | 1 |
| Schneck, MJ | 1 |
| Norrving, B | 1 |
| Ford, GA | 1 |
| Bryant, CA | 1 |
| Mangoni, AA | 1 |
| Jackson, SH | 1 |
| Avorn, J | 1 |
| Chen, M | 1 |
| Hartley, R | 1 |
| Pavlova, SI | 1 |
| Van Horn, G | 1 |
| Arnett, FC | 1 |
| Dimachkie, MM | 1 |
| Rockwood, K | 1 |
| Ebly, E | 1 |
| Hachinski, V | 1 |
| Hogan, D | 1 |
| Moroney, JT | 1 |
| Tseng, CL | 1 |
| Paik, MC | 1 |
| Mohr, JP | 1 |
| Desmond, DW | 1 |
| Zipper, SG | 1 |
| Lambert, S | 1 |
| Seemann, WR | 1 |
| Baer, U | 1 |
| Schlisske, K | 1 |
| Cohen, SA | 1 |
| Hershey, LA | 1 |
| Jaffe, DF | 1 |
| Greenough, PG | 1 |
| Yang, SL | 1 |
| Murray, RM | 1 |
| Greene, JG | 1 |
| Adams, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226] | Phase 4 | 15,480 participants (Actual) | Interventional | 2005-03-31 | Active, not recruiting | ||
| LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.[NCT03451591] | Phase 2/Phase 3 | 363 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White[NCT00847860] | Phase 4 | 200 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Stroke and Coated-Platelets - A Translational Research Initiative[NCT04698031] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-03-30 | Recruiting | ||
| Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)[NCT03061006] | Phase 4 | 101 participants (Actual) | Interventional | 2017-04-03 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 157 |
| Placebo Aspirin | 158 |
"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 833 |
| Placebo Aspirin | 936 |
| Omega-3 | 882 |
| Placebo Omega-3 | 887 |
"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 897 |
| Placebo Aspirin | 887 |
| Omega-3 | 894 |
| Placebo Omega-3 | 890 |
Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 166 |
| Placebo Omega-3 | 135 |
Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 97 |
| Placebo Aspirin | 96 |
| Omega-3 | 103 |
| Placebo Omega-3 | 90 |
Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 332 |
| Placebo Aspirin | 294 |
| Omega-3 | 323 |
| Placebo Omega-3 | 303 |
Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo Aspirin | 86 |
| Omega-3 | 94 |
| Placebo Omega-3 | 80 |
Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 50 |
| Placebo Aspirin | 59 |
| Omega-3 | 55 |
| Placebo Omega-3 | 54 |
Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 83 |
| Placebo Omega-3 | 99 |
Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 25 |
| Placebo Aspirin | 30 |
| Omega-3 | 23 |
| Placebo Omega-3 | 32 |
Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 87 |
| Placebo Aspirin | 82 |
Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 101 |
| Placebo Aspirin | 103 |
| Omega-3 | 104 |
| Placebo Omega-3 | 100 |
Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 26 |
| Placebo Aspirin | 31 |
| Omega-3 | 25 |
| Placebo Omega-3 | 32 |
Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 38 |
| Placebo Aspirin | 34 |
| Omega-3 | 35 |
| Placebo Omega-3 | 37 |
'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 748 |
| Placebo Aspirin | 792 |
| Omega-3 | 752 |
| Placebo Omega-3 | 788 |
Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 309 |
| Placebo Aspirin | 315 |
| Omega-3 | 305 |
| Placebo Omega-3 | 319 |
Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 105 |
| Placebo Aspirin | 122 |
| Omega-3 | 100 |
| Placebo Omega-3 | 127 |
Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 18 |
| Placebo Aspirin | 21 |
| Omega-3 | 17 |
| Placebo Omega-3 | 22 |
Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 126 |
| Placebo Aspirin | 157 |
| Omega-3 | 158 |
| Placebo Omega-3 | 125 |
Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 67 |
| Placebo Aspirin | 70 |
| Omega-3 | 61 |
| Placebo Omega-3 | 76 |
Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 82 |
| Placebo Aspirin | 69 |
| Omega-3 | 73 |
| Placebo Omega-3 | 78 |
Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 3 |
| Placebo Aspirin | 4 |
| Omega-3 | 3 |
| Placebo Omega-3 | 4 |
"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 314 |
| Placebo Aspirin | 245 |
"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 658 |
| Placebo Aspirin | 743 |
| Omega-3 | 689 |
| Placebo Omega-3 | 712 |
7 reviews available for aspirin and Dementia
| Article | Year |
|---|---|
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cognition; Cognition Disorders; Dementia; Humans; | 2017 |
Subclinical Cerebrovascular Disease: Epidemiology and Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Brain Infarction; Dementia; Female; Humans; | 2019 |
Primary prevention: do the very elderly require a different approach?
Topics: Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dementia; Humans; Hydr | 2015 |
[Lacunar infarcts].
Topics: Adult; Aged; Aspirin; Autopsy; Brain; Carotid Stenosis; Cerebral Infarction; Dementia; Female; Fibri | 2003 |
Stroke, dementia, and drug delivery.
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Clinical Trials as Topic; Dementia; Fibrinolytic | 2004 |
10 trials available for aspirin and Dementia
| Article | Year |
|---|---|
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
Topics: Aspirin; Cognition; Cognitive Dysfunction; Dementia; Diabetes Mellitus; Humans | 2022 |
How does the onset of physical disability or dementia in older adults affect economic wellbeing and co-payments for health care? the impact of gender.
Topics: Aged; Aspirin; Australia; Dementia; Disabled Persons; Female; Health Expenditures; Humans; Male | 2022 |
Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cohort Studies; Dementia; Diabetes Mellitu | 2020 |
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cognitive Dysfunction; De | 2020 |
Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing Events in the Elderly Study and Its Predictive Capacity for Disability-Free Survival.
Topics: Aged; Aged, 80 and over; Aspirin; Dementia; Disabled Persons; Female; Frail Elderly; Frailty; Geriat | 2022 |
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Aging; Aspirin; Australia | 2017 |
Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Dementia; Disabled Persons; Disea | 2018 |
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardi | 2013 |
Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia.
Topics: Aged; Aspirin; Cerebellum; Cognition Disorders; Dementia; Drugs, Chinese Herbal; Female; Ginkgo bilo | 2015 |
Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia.
Topics: Aged; Aged, 80 and over; Aspirin; Cognition Disorders; Dementia; Female; Folic Acid; Follow-Up Studi | 2003 |
25 other studies available for aspirin and Dementia
| Article | Year |
|---|---|
Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cognitive Dysfunction; Dementi | 2021 |
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Dementia; Humans; Warfar | 2022 |
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia.
Topics: Administration, Oral; American Heart Association; Apolipoprotein B-100; Aspirin; Biomarkers; Dementi | 2022 |
The end of aspirin for dementia prevention in diabetes?
Topics: Aspirin; Cardiovascular Diseases; Cognition; Dementia; Diabetes Mellitus; Humans; Platelet Aggregati | 2022 |
Latest Canadian consensus conference on the diagnosis and treatment of dementia for primary care clinicians.
Topics: Aspirin; Canada; Case Management; Dementia; Humans; Primary Health Care | 2022 |
Impact of dementia and drug compliance on patients with acute myocardial infarction.
Topics: Aspirin; Dementia; Humans; Medication Adherence; Myocardial Infarction; Retrospective Studies | 2023 |
Incidence and Predictors of Aspirin Discontinuation in Older Adult Veteran Nursing Home Residents at End of Life.
Topics: Aged; Aged, 80 and over; Aspirin; Chronic Disease; Dementia; Deprescriptions; Female; Heart Disease | 2020 |
Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study.
Topics: Age of Onset; Aged; Aspirin; Cohort Studies; Dementia; Depression; Female; Humans; Incidence; Male; | 2020 |
Aspirin in people with dementia.
Topics: Aspirin; Cognition Disorders; Dementia; Humans | 2021 |
A case report of late onset psychosis with dementia and aspirin and caffeine addiction.
Topics: Age of Onset; Aspirin; Caffeine; Central Nervous System Agents; Dementia; Diagnosis, Differential; H | 2015 |
Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type?
Topics: Alzheimer Disease; Animals; Antioxidants; Aspirin; Cognition Disorders; Dementia; Disease Models, An | 2008 |
[Iatrogenic dementia and extrapyramidal syndrome: rare adverse effect of valproic acid-aspirin combination].
Topics: Aged; Anticonvulsants; Aspirin; Basal Ganglia Diseases; Dementia; Drug Interactions; Drug Therapy, C | 2010 |
Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dementia; F | 2009 |
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil.
Topics: Aged, 80 and over; Anticonvulsants; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 2011 |
Superficial siderosis of the central nervous system: a rare cause of dementia with therapeutic consequences.
Topics: Aged; Aspirin; Dementia; Hemosiderosis; Humans; Magnetic Resonance Imaging; Male; Memory; Neuropsych | 2012 |
"Silent" strokes and dementia.
Topics: Aspirin; Brain Infarction; Dementia; Humans; Platelet Aggregation Inhibitors; Stroke | 2003 |
Scientific versus commercial sources of influence on the prescribing behavior of physicians.
Topics: Advertising; Aged; Aspirin; Boston; Cerebrovascular Circulation; Decision Making; Dementia; Dextropr | 1982 |
[Changes in coagulographic indices of patients with cerebral atherosclerosis complicated by mental disorders during the treatment process].
Topics: Aged; Aspirin; Blood Coagulation; Dementia; Drug Therapy, Combination; Female; Humans; Intracranial | 1980 |
Reversible dementia and chorea in a young woman with the lupus anticoagulant.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Autoimmune Diseases; Chorea; Dementia; Depression; Diagno | 1996 |
Presence and treatment of vascular risk factors in patients with vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Cognition Disorders; Dementia; Diabetes Complic | 1997 |
Treatment for the secondary prevention of stroke in older patients: the influence of dementia status.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dementia; Drug Utilizat | 1999 |
[Sneddon syndrome: vasculitis or thrombotic disorder?].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Dementia; Fatal O | 2000 |
Delirious woman with disabling headaches.
Topics: Acid-Base Imbalance; Aspirin; Dementia; Female; Headache; Humans; Medication Errors; Middle Aged; Se | 1988 |
Validation of cognitive and functional assessment instruments in vascular dementia.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Dementia; Double-Blind Method; Female; Humans; Mal | 1987 |
Analgesics abuse and dementia.
Topics: Aged; Analgesics; Aspirin; Brain; Dementia; Female; Humans; Intelligence Tests; Male; Middle Aged; P | 1971 |